Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lemtrada 'Behaves Like Chemotherapy For MS' Suggests 5-Year Efficacy Data

This article was originally published in Scrip

Executive Summary

Around two thirds of patients on Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) need no additional treatment up to four years after the two courses of infusion that make up its standard treatment schedule, according to Genzyme's Mike Panzara, therapeutic area head of MS, neurology and ophthalmology.

Advertisement

Related Content

ECTRIMS 2016: Alemtuzumab Benefits Continue Six Years Post-Treatment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel